153 related articles for article (PubMed ID: 1282594)
1. Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol.
Spinelli W; Parsons RW; Colatsky TJ
J Cardiovasc Pharmacol; 1992 Dec; 20(6):913-22. PubMed ID: 1282594
[TBL] [Abstract][Full Text] [Related]
2. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs.
Wallace AA; Stupienski RF; Brookes LM; Selnick HG; Claremon DA; Lynch JJ
J Cardiovasc Pharmacol; 1991 Nov; 18(5):687-95. PubMed ID: 1723765
[TBL] [Abstract][Full Text] [Related]
3. Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: specificity of IK block and lack of reverse use dependence in cat ventricular myocytes.
Spinelli W; Moubarak IF; Parsons RW; Colatsky TJ
Cardiovasc Res; 1993 Sep; 27(9):1580-91. PubMed ID: 8287434
[TBL] [Abstract][Full Text] [Related]
4. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs.
Gwilt M; Blackburn KJ; Burges RA; Higgins AJ; Milne AA; Solca AM
Eur J Pharmacol; 1992 May; 215(2-3):137-44. PubMed ID: 1396982
[TBL] [Abstract][Full Text] [Related]
5. Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
Ellingboe JW; Spinelli W; Winkley MW; Nguyen TT; Parsons RW; Moubarak IF; Kitzen JM; Von Engen D; Bagli JF
J Med Chem; 1992 Feb; 35(4):705-16. PubMed ID: 1542097
[TBL] [Abstract][Full Text] [Related]
6. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle.
Baskin EP; Serik CM; Wallace AA; Brookes LM; Selnick HG; Claremon DA; Lynch JJ
J Cardiovasc Pharmacol; 1991 Sep; 18(3):406-14. PubMed ID: 1720841
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
Brooks RR; Finch SL
Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent.
Gwilt M; Dalrymple HW; Burges RA; Blackburn KJ; Dickinson RP; Cross PE; Higgins AJ
J Cardiovasc Pharmacol; 1991 Mar; 17(3):376-85. PubMed ID: 1711597
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic effects of sotalol on the immature mammalian heart.
Houyel L; Fournier A; Ducharme G; Chartrand C; Davignon A
J Cardiovasc Pharmacol; 1992 Jan; 19(1):134-9. PubMed ID: 1375680
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog.
Duker G; Almgren O; Carlsson L
J Cardiovasc Pharmacol; 1992 Sep; 20(3):458-65. PubMed ID: 1279293
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031, and MK-499.
Baskin EP; Lynch JJ
J Cardiovasc Pharmacol; 1994 Aug; 24(2):199-208. PubMed ID: 7526051
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
Sen L; Cui G; Sakaguchi Y; Singh BN
J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614
[TBL] [Abstract][Full Text] [Related]
13. Investigation of electrophysiologic mechanisms for the antiarrhythmic actions of R 56865 in cardiac glycoside toxicity.
Damiano BP; Stump GL; Yagel SK
J Cardiovasc Pharmacol; 1991 Sep; 18(3):415-28. PubMed ID: 1720842
[TBL] [Abstract][Full Text] [Related]
14. Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol.
Fiset C; Drolet B; Hamelin BA; Turgeon J
J Pharmacol Exp Ther; 1997 Oct; 283(1):148-56. PubMed ID: 9336319
[TBL] [Abstract][Full Text] [Related]
15. Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
Lu HR; Remeysen P; De Clerck F
J Cardiovasc Pharmacol; 1995 Jul; 26(1):132-6. PubMed ID: 7564354
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart.
Fazekas T; Carlsson L; Scherlag BJ; Mabo P; Poty H; Palmer M; Patterson E; Berlin KD; Garrison GL; Lazzara R
J Cardiovasc Pharmacol; 1996 Aug; 28(2):182-91. PubMed ID: 8856472
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction.
Feld GK; Venkatesh N; Singh BN
Circulation; 1986 Jul; 74(1):197-204. PubMed ID: 3708774
[TBL] [Abstract][Full Text] [Related]
18. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Wang J; Feng J; Nattel S
Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
[TBL] [Abstract][Full Text] [Related]
19. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.
Kovács A; Gyönös I; Magyar J; Bányász T; Nánási PP; Spedding M; Szénási G
J Cardiovasc Pharmacol; 2001 Jan; 37(1):78-88. PubMed ID: 11152377
[TBL] [Abstract][Full Text] [Related]
20. Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs.
Koerner JE; Dage RC
J Cardiovasc Pharmacol; 1990 Sep; 16(3):383-93. PubMed ID: 1700208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
